Pfizer Thelin development (correction)
Pfizer has commenced enrollment of patients in a Phase III study for Thelin (sitaxsentan) to support a U.S. filing for the treatment of pulmonary arterial hypertension. The "Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil" (SR-PAAS) is expected to be completed by June 2010. An article in "The Pink Sheet" inaccurately stated that Pfizer was likely to abandon a Thelin NDA (1"The Pink Sheet" Jan. 5, 2009, p. 8)
You may also be interested in...
Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said
At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.